Roche’s Perjeta nabs speedy FDA nod in early breast cancer

Tracy Staton Perjeta is now the first cancer drug approved to treat patients before surgery. Developed by Roche's Genentech unit, and already approved for women with advanced HER2-positive ...

Former Bristol-Myers Chemist Sentenced To Life For Murdering Hubby

esilverman Do you remember Tianle Li? She is the former Bristol-Myers Squibb chemist who was convicted two months ago for murdering her estranged husband by giving him a toxic ...

AstraZeneca CEO celebrates 1st anniversary with promising lung cancer data

John Carroll The promising early results on AstraZeneca's lung cancer drug AZD9291 won't convince anyone that the troubled company is on the turnaround trail, but it's a ...

What happens to the FDA in a government shutdown?

Damian Garde With hope for congressional compromise waning by the hour, the federal government is bracing for its first shutdown in 17 years, and for the FDA, that means furloughing ...

Lilly fails to persuade Medicare to pay for Alzheimer’s imaging drug

Tracy Staton The Centers for Medicare & Medicaid Services has handed down its final decision on Eli Lilly's Alzheimer's imaging agent Amyvid. The final answer, after appeals ...

Amarin Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients

barbara.lempert    Study Evaluating the Effectiveness of Vascepa(R) in Reducing    Major Cardiovascular Events in a High-Risk Patient Population BEDMINSTER, N.J., and DUBLIN, ...

A Thaw Between Roche And Novartis? What About A Merger?

esilverman Will Roche and Novartis work more closely together and even consider a merger? Now that both drugmakers have new chairmen – replacing a pair who had famously icy ...

Lundbeck to cull 200 staffers in cost-cutting drive

John Carroll The pharma company expects to save about a half billion Danish kroner annually in the move. FierceBiotech News

Lundbeck’s cost-saving reorg plan to claim up to 200 jobs

Tracy Staton Supply-chain simplification and new procurement processes are also part of the plan. FiercePharma News

Roche Report High Response Rate in Lung Cancer Drug Trial

barbara.lempert Roche presents updated data on investigational cancer immunotherapy MPDL3280A (anti-PDL1) in lung cancer at ECC 2013 Rapid and durable responses observed in ...

Nektar Phase II Trial for NKTR-181 Misses Primary Endpoint

mia.burns Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee Company to Host Conference ...

New Lucentis Data Reinforces Profile Across Four Indications

mia.burns New data for Novartis drug Lucentis® reinforces transformational efficacy and well-established safety profile across four indications     Pivotal myopic CNV trials ...
Page 1 of 2412345...1020...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS